A Phase 3 interventional study of Placebo and Secukinumab 2 mL form in Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 52 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.
Among the 54 studies testing secukinumab in Psoriasis, this one is the 15th largest by enrollment, is one of 4 that started in 2016, is one of 24 in phase 3, and was the 34th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Singapore General Hospital · Sites in Singapore
Ages 22–90
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 24 · Phase 4 17
First in 2007; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 214 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 124 across the 54 interventional studies. Of the 46 that completed or were terminated, 38 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
68 studies in Psoriasis by Novartis: 3 open now, 4 under way, none of them phase 3. Of 61 finished, 41 (67%) have results posted.
Among the 68 studies in Psoriasis by Novartis, this one is the 22nd largest by enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2016, is one of 30 in phase 3, and was the 42nd registered.
Novartis’s Psoriasis studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing secukinumab in Psoriasis, from their registry updates:
Among Novartis’s 68 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of the study was to demonstrate efficacy, safety and tolerability of 2 mL pre-filled syringe of 300 mg secukinumab in treatment of moderate to severe plaque psoriasis.
This is a 52-weeks multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in 24 subjects with moderate to severe plaque-type psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects eligible for inclusion in this study must fulfill all of the following criteria:
Moderate to severe psoriasis as defined at Randomization by:
Candidate for systemic therapy. This is defined as a subject having moderate to severe chronic plaque-type psoriasis that is inadequately controlled by
Exclusion Criteria:
Ongoing use of prohibited treatments. detailed in the protocol have to be adhered to. Subjects not willing to limit UV light exposure (e.g., sunbathing and/or the use of tanning devices) during the course of the study will be considered not eligible for this study since UV light exposure is prohibited.
Note: administration of 6 weeks prior to Randomization or during the study period is also prohibited.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo, provided in a 2 mL pre-filled syringe Placebo, provided in a 1 mL pre-filled syringe
Drug: Placebo
Secukinumab 300 mg, provided in a 2 mL pre-filled syringe
Drug: Secukinumab 2 mL form
Secukinumab 300 mg provided in 2 pre-filled syringes of 1 mL/150 mg (current approved form)
Drug: Secukinumab 1 mL form
2 mL + 2 x 1 mL Placebo s.c. at randomization, weeks 1, 3, and 4, thereafter 4-weekly until week 48
Secukinumab 300 mg/2mL + 2 x 1 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
Secukinumab 150 mg/1mL x 2 + 2 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
Participants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of Treatment
Number of participants who achieved ≥ 75% reduction in PASI compared to baseline PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
Time frame: 12 weeks
Participants With IGA Mod 2011 0 or 1 After 12 Weeks of Treatment
The Investigator's Global Assessment (IGA) mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1. Number of participants who achieved IGA mod 2011 0 or 1 and improved by at least 2 points on the IGA scale compared to baseline
Time frame: 12 weeks
Participants With PASI 90 After 12 Weeks of Treatment
Number of participants who achieved ≥ 90% and 100% reduction in PASI compared to baseline
Time frame: 12 weeks
Number of Participants With PASI 100 Response After 12 Weeks of Treatment
Participants who achieved 100% reduction in PASI compared to baseline
Time frame: 12 weeks
Number of Participants Achieving PASI 50/75/90/100 Response or IGA 0 or 1 Response
PASI response over time up to week 52: Number of participants who achieved ≥ 50%, 75%, 90% and 100% reduction in PASI and achieve IGA mod 2011 0 or 1 and improved by at least 2 points on the IGA scale compared to baseline
Time frame: up to week 52
| Milestone | Secukinumab 2 mL PFS | Secukinumab 2 x 1 mL PFS | Placebo | Secukinumab 2 mL PFS Following Placebo | Secukinumab 2 x 1 mL PFS Following Placebo |
|---|---|---|---|---|---|
| Started | 72 | 71 | 71 | 0 | 0 |
| Completed | 72 | 69 | 69 | 0 | 0 |
| Not completed | 0 | 2 | 2 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 0 | 0 |
| Milestone | Secukinumab 2 mL PFS | Secukinumab 2 x 1 mL PFS | Placebo | Secukinumab 2 mL PFS Following Placebo | Secukinumab 2 x 1 mL PFS Following Placebo |
|---|---|---|---|---|---|
| Started | 72 | 69 | 0 | 34 | 34 |
| Completed | 67 | 66 | 0 | 32 | 33 |
| Not completed | 5 | 3 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 2 | 0 | 2 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 1 |
Number of participants who achieved ≥ 75% reduction in PASI compared to baseline PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
| participants | Secukinumab 2 mL PFS | Placebo |
|---|---|---|
| Participants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of Treatment | 64 | 1 |
Number of participants who achieved ≥ 90% and 100% reduction in PASI compared to baseline
| participants | Secukinumab 2 mL PFS | Placebo |
|---|---|---|
| Participants With PASI 90 After 12 Weeks of Treatment | 48 | 1 |
Participants who achieved 100% reduction in PASI compared to baseline
| participants | Secukinumab 2 mL PFS | Secukinumab 2 x 1 mL PFS | Placebo |
|---|---|---|---|
| Number of Participants With PASI 100 Response After 12 Weeks of Treatment | 28 | 26 | 0 |
PASI response over time up to week 52: Number of participants who achieved ≥ 50%, 75%, 90% and 100% reduction in PASI and achieve IGA mod 2011 0 or 1 and improved by at least 2 points on the IGA scale compared to baseline
| participants | Secukinumab 2 mL PFS | Secukinumab 2 x 1 mL PFS | Placebo | Secukinumab 2 mL PFS Following Placebo | Secukinumab 2 x 1 mL PFS Following Placebo |
|---|---|---|---|---|---|
| Week 1 IGA 0/1 | 1 | 0 | 0 | 0 | 0 |
| Week 1 PASI 50 | 5 | 5 | 1 | 0 | 1 |
| Week 1 PASI 75 | 0 | 2 | 0 | 0 | 0 |
| Week 1 PASI 90 | 0 | 0 | 0 | 0 | 0 |
| Week 1 PASI 100 | 0 | 0 | 0 | 0 | 0 |
| Week 2 IGA 0/1 | 2 | 1 | 1 | 0 | 1 |
| Week 2 PASI 50 | 18 | 28 | 1 | 1 | 0 |
| Week 2 PASI 75 | 4 | 5 | 0 | 0 | 0 |
| Week 2 PASI 90 | 0 | 1 | 0 | 0 | 0 |
| Week 2 PASI 100 | 0 | 1 | 0 | 0 | 0 |
| Week 3 IGA 0/1 | 6 | 11 | 1 | 0 | 1 |
| Week 3 PASI 50 | 39 | 40 | 5 | 3 | 1 |
| Week 3 PASI 75 | 14 | 17 | 0 | 0 | 0 |
| Week 3 PASI 90 | 4 | 4 | 0 | 0 | 0 |
| Week 3 PASI 100 | 0 | 1 | 0 | 0 | 0 |
| Week 4 IGA 0/1 | 19 | 23 | 0 | 0 | 0 |
| Week 4 PASI 50 | 53 | 52 | 6 | 5 | 1 |
| Week 4 PASI 75 | 29 | 32 | 1 | 1 | 0 |
| Week 4 PASI 90 | 10 | 13 | 0 | 0 | 0 |
| Week 4 PASI 100 | 3 | 3 | 0 | 0 | 0 |
| Week 8 IGA 0/1 | 43 | 41 | 0 | 0 | 0 |
| Week 8 PASI 50 | 66 | 60 | 5 | 3 | 2 |
| Week 8 PASI 75 | 53 | 51 | 0 | 0 | 0 |
| Week 8 PASI 90 | 35 | 31 | 0 | 0 | 0 |
| Week 8 PASI 100 | 8 | 11 | 0 | 0 | 0 |
| Week 12 IGA 0/1 | 55 | 49 | 1 | 0 | 0 |
| Week 12 PASI 50 | 67 | 61 | 5 | 2 | 2 |
| Week 12 PASI 75 | 64 | 58 | 1 | 0 | 0 |
| Week 12 PASI 90 | 48 | 50 | 1 | 0 | 0 |
| Week 12 PASI 100 | 28 | 26 | 0 | 0 | 0 |
| Week 16 IGA 0/1 | 57 | 52 | 0 | 14 | 5 |
| Week 16 PASI 50 | 69 | 61 | 0 | 27 | 20 |
| Week 16 PASI 75 | 65 | 60 | 0 | 17 | 13 |
| Week 16 PASI 90 | 56 | 55 | 0 | 8 | 4 |
| Week 16 PASI 100 | 37 | 31 | 0 | 5 | 1 |
| Week 28 IGA 0/1 | 64 | 54 | 0 | 30 | 25 |
| Week 28 PASI 50 | 71 | 66 | 0 | 33 | 30 |
| Week 28 PASI 75 | 69 | 60 | 0 | 32 | 28 |
| Week 28 PASI 90 | 62 | 56 | 0 | 26 | 21 |
| Week 28 PASI 100 | 44 | 34 | 0 | 16 | 12 |
| Week 40 IGA 0/1 | 60 | 55 | 0 | 28 | 25 |
| Week 40 PASI 50 | 69 | 67 | 0 | 33 | 33 |
| Week 40 PASI 75 | 66 | 63 | 0 | 31 | 31 |
| Week 40 PASI 90 | 58 | 57 | 0 | 27 | 24 |
| Week 40 PASI 100 | 40 | 37 | 0 | 20 | 17 |
| Week 52 IGA 0/1 | 55 | 55 | 0 | 28 | 26 |
| Week 52 PASI 50 | 67 | 67 | 0 | 31 | 32 |
| Week 52 PASI 75 | 63 | 62 | 0 | 30 | 31 |
| Week 52 PASI 90 | 54 | 58 | 0 | 25 | 26 |
| Week 52 PASI 100 | 40 | 37 | 0 | 20 | 16 |
The Investigator's Global Assessment (IGA) mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1. Number of participants who achieved IGA mod 2011 0 or 1 and improved by at least 2 points on the IGA scale compared to baseline
| participants | Secukinumab 2 mL PFS | Placebo |
|---|---|---|
| Participants With IGA Mod 2011 0 or 1 After 12 Weeks of Treatment | 55 | 1 |
Collected over AEs and SAEs were collected for the maximum duration of treatment and follow up for a participant per protocol for approximately 52 weeks. All cause mortality (deaths) was collected from First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV) up to a maximum of 52 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Secukinumab 300 mg (2mL PFS) | 0/72 (0%) | 0/72 (0%) | 33/72 (45.8%) |
| AIN457 300 mg (2x1mL PFS) | 0/71 (0%) | 1/71 (1.4%) | 39/71 (54.9%) |
| Placebo | 0/71 (0%) | 2/71 (2.8%) | 29/71 (40.8%) |
| Any AIN457 300 mg (2mL PFS) | 0/106 (0%) | 8/106 (7.5%) | 60/106 (56.6%) |
| Any Secukuinumab 300 mg (2x1mL PFS) | 0/105 (0%) | 5/105 (4.8%) | 68/105 (64.8%) |
| Any Secukinumab 300 mg | 0/211 (0%) | 13/211 (6.2%) | 128/211 (60.7%) |
| Event | Secukinumab 300 mg (2mL PFS) | AIN457 300 mg (2x1mL PFS) | Placebo | Any AIN457 300 mg (2mL PFS) | Any Secukuinumab 300 mg (2x1mL PFS) | Any Secukinumab 300 mg |
|---|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 0/72 | 1/71 | 0/71 | 1/106 | 1/105 | 2/211 |
| Fibula fractureInjury, poisoning and procedural complications | 0/72 | 0/71 | 1/71 | 0/106 | 0/105 | 0/211 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/72 | 0/71 | 1/71 | 0/106 | 0/105 | 0/211 |
| Myocardial infarctionCardiac disorders | 0/72 | 0/71 | 0/71 | 0/106 | 1/105 | 1/211 |
| Pancreatitis acuteGastrointestinal disorders | 0/72 | 0/71 | 0/71 | 0/106 | 1/105 | 1/211 |
| Pharyngitis bacterialInfections and infestations | 0/72 | 0/71 | 0/71 | 0/106 | 1/105 | 1/211 |
| Rib fractureInjury, poisoning and procedural complications | 0/72 | 0/71 | 0/71 | 0/106 | 1/105 | 1/211 |
| HaemothoraxRespiratory, thoracic and mediastinal disorders | 0/72 | 0/71 | 0/71 | 0/106 | 1/105 | 1/211 |
| HypoventilationRespiratory, thoracic and mediastinal disorders | 0/72 | 0/71 | 0/71 | 0/106 | 1/105 | 1/211 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/72 | 0/71 | 0/71 | 0/106 | 1/105 | 1/211 |
| Event | Secukinumab 300 mg (2mL PFS) | AIN457 300 mg (2x1mL PFS) | Placebo | Any AIN457 300 mg (2mL PFS) | Any Secukuinumab 300 mg (2x1mL PFS) | Any Secukinumab 300 mg |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 7/72 | 8/71 | 8/71 | 13/106 | 17/105 | 30/211 |
| HeadacheNervous system disorders | 6/72 | 6/71 | 3/71 | 10/106 | 8/105 | 18/211 |
| PruritusSkin and subcutaneous tissue disorders | 5/72 | 3/71 | 3/71 | 10/106 | 4/105 | 14/211 |
| InfluenzaInfections and infestations | 0/72 | 1/71 | 0/71 | 2/106 | 8/105 | 10/211 |
| DiarrhoeaGastrointestinal disorders | 2/72 | 3/71 | 0/71 | 6/106 | 6/105 | 12/211 |
| FatigueGeneral disorders | 2/72 | 0/71 | 1/71 | 6/106 | 3/105 | 9/211 |
| Back painMusculoskeletal and connective tissue disorders | 4/72 | 3/71 | 2/71 | 6/106 | 4/105 | 10/211 |
| Respiratory tract infection viralInfections and infestations | 2/72 | 0/71 | 1/71 | 2/106 | 5/105 | 7/211 |
| RhinitisInfections and infestations | 1/72 | 1/71 | 1/71 | 4/106 | 5/105 | 9/211 |
| Upper respiratory tract infectionInfections and infestations | 1/72 | 1/71 | 2/71 | 5/106 | 5/105 | 10/211 |
| Age, Customized(Participants) | Secukinumab 2 mL PFS | Secukinumab 2 x 1 mL PFS | Placebo | Total |
|---|---|---|---|---|
| <65 years | 68 | 64 | 68 | 200 |
| >=65 years | 4 | 7 | 3 | 14 |
| >=75 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Secukinumab 2 mL PFS | Secukinumab 2 x 1 mL PFS | Placebo | Total |
|---|---|---|---|---|
| Female | 28 | 28 | 25 | 81 |
| Male | 44 | 43 | 46 | 133 |
| Race/Ethnicity, Customized(Participants) | Secukinumab 2 mL PFS | Secukinumab 2 x 1 mL PFS | Placebo | Total |
|---|---|---|---|---|
| Caucasian | 64 | 64 | 66 | 194 |
| Black | 2 | 1 | 1 | 4 |
| Asian | 4 | 4 | 4 | 12 |
| Pacific Islander | 0 | 1 | 0 | 1 |
| Other | 2 | 1 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Dec 2016 to primary completion in Aug 2017, 7 months.
Results were first posted in Jun 2019, 1 year 10 months after primary completion. A results delay was requested in Jul 2018.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab